Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs

References

• Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008;3:557–86.
   PubMed Web of Science ®Google Scholar
• Bümming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: A centre-based study of 17 patients. Br J Cancer 2003;89:460–4.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J, editors. GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): A meta-analysis based on 1640 patients. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):A10004.
   Google Scholar
• Wang WL, Conley A, Reynoso D, Nolden L, Lazar AJ, George S, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011;67(Suppl 1):S15–24.
   Google Scholar
• Younus J, Verma S, Franek J, Coakley N. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate- resistant patients: Recommendations and evidence. Curr Oncol 2010;17:4–10.
   PubMed Web of Science ®Google Scholar
• Nilsson B, Nilsson O, Ahlman H. Treatment of gastrointestinal stromal tumours: Imatinib, sunitinib – and then?Expert Opin Investig Drugs 2009;18:457–68.
   PubMed Web of Science ®Google Scholar
• Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008;105:8387–92.
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, et al. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res 2010;29:173.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004;31:803–10.
   PubMed Web of Science ®Google Scholar
• Palmieri G, Montella L, Aiello C, Barbieri F, Di Vizio D, Schulz S, et al. Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. Amino Acids 2007;32:395–400.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53–73.
   PubMed Web of Science ®Google Scholar
• Andersson P, Forssell-Aronsson E, Johanson V, Wängberg B, Nilsson O, Fjälling M, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med 1996;37:2002–6.
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33: 459–65.
   PubMed Web of Science ®Google Scholar
• Arne G, Kristiansson E, Nerman O, Kindblom LG, Ahlman H, Nilsson B, et al. Expression profiling of GIST: CD133 is associated with KITexon 11 mutations, gastric location and poor prognosis. Int J Cancer 2011;129:1149–61.
   PubMed Web of Science ®Google Scholar
• Bümming P, Nilsson B, Sörensen J, Nilsson O, Ahlman H. Use of 2-tracer PET to diagnose gastrointestinal stromal tumour and pheochromocytoma in patients with Carney triad and neurofibromatosis type 1. Scand J Gastroenterol 2006;41:626–30.
   PubMed Web of Science ®Google Scholar
• Teunissen JJ, Kwekkeboom DJ, Krenning EP. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 2006; 17:19–25.
   PubMed Web of Science ®Google Scholar
• Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998;77:632–7.
   PubMed Web of Science ®Google Scholar
• Forssell-Aronsson E, Bernhardt P, Nilsson O, Tisell LE, Wängberg B, Ahlman H. Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide. Acta Oncol 2004;43:436–42.
   PubMed Web of Science ®Google Scholar
• Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010;29:19.
   PubMed Web of Science ®Google Scholar
• Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): Subtype selective internalization or upregulation. Endocrinology 1996;137:4046–9.
   PubMed Web of Science ®Google Scholar
• Roth A, Kreienkamp HJ, Nehring RB, Roosterman D, Meyerhof W, Richter D. Endocytosis of the rat somatostatin receptors: Subtype discrimination, ligand specificity, and delineation of carboxy-terminal positive and negative sequence motifs. DNA Cell Biol 1997;16:111–9.
   PubMed Web of Science ®Google Scholar